## Jeffrey Wolf

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9341016/publications.pdf

Version: 2024-02-01

8	196	7	8
papers	citations	h-index	g-index
9	9	9	439
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Digital Life Coaching During Stem Cell Transplantation: Development and Usability Study. JMIR Formative Research, 2022, 6, e33701.	1.4	3
2	Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 126.	17.0	19
3	Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Advances, 2021, 5, 5344-5348.	5.2	16
4	Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Advances, 2020, 4, 3295-3301.	5.2	20
5	A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2020, 61, 1211-1219.	1.3	10
6	Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Advances, 2020, 4, 2163-2171.	5.2	21
7	A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 29-34.	0.4	53
8	Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 131-139.e1.	0.4	54